Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 701 - 750 out of 14,479

Document Document Title
WO/2017/072021A1
The present invention relates to compounds of general formula (I), wherein D 1 to D 3, -A-, n, R 1, R 2, Y 1, L and y2 are defined as in claim 1, which have valuable pharmacological properties, in particular are inhibitors of plasma kall...  
WO/2017/072721A1
The disclosures herein relate to novel compounds of formula (I) wherein R1, R2, R3 and R4 are as defined herein, and their use in treating, preventing, ameliorating, controlling or reducing cerebrovascular or vascular disorders associate...  
WO/2017/075377A1
The present invention relates to an amorphous solid form of (4S)-7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydr oimidazo[1,5,4-de][1,4]benzoxazin-2(1H)-one, and processes for its preparation, which is an inhibitor of BET protein...  
WO/2017/073942A1
The present disclosure relates to an electron buffering material, and an organic electroluminescent device comprising a first electrode, a second electrode facing the first electrode, a light-emitting layer between the first electrode an...  
WO/2017/072039A1
The invention relates to novel compounds of formulae (I) or (Γ) (formula I, II) wherein R1, R2, R3, Aa, Ab, Ac, Ad, Ae, Q and n have the meanings indicated in the description, to the use thereof as acaricides and/or insecticides for con...  
WO/2017/073743A1
The present invention provides: a DHODH inhibitor which contains a tricyclic compound represented by formula (I) or a pharmaceutically acceptable salt thereof or the like as an active ingredient; and others. [In the formula, R3a and R3b ...  
WO/2017/067664A1
The present invention relates to oxa-diazaspiro compounds having pharmacological activity towards the sigma (σ) receptor, to processes of preparation of such compounds, to pharmaceutical compositions comprising them, and to their use in...  
WO/2017/067663A1
The present invention relates to oxa-azaspiro compounds having pharmacological activity towards the sigma (σ) receptor, to processes of preparation of such compounds, to pharmaceutical compositions comprising them, and to their use in t...  
WO/2017/070081A1
The disclosed subject matter provides pyrazolone derivative compounds, pharmaceutical compositions comprising such compounds, kits comprising such compounds, and methods of using such compounds or pharmaceutical compositions. In particul...  
WO/2017/066863A1
The present invention provides compounds of Formula I: wherein Y, AA, W, R3, R2, R4, R5, R6, R7, X1, X2, X3, X4 and X5 are as defined herein, or a stereoisomer, tautomer, pharmaceutically acceptable salt, prodrug or esters or solvate for...  
WO/2017/069226A1
A compound represented by general formula [I] (in the formula, X represents N or the like, Y represents CH or the like, RA represents an optionally substituted cycloalkyl group or the like, R1 represents an alkyl group or the like, R2 re...  
WO/2017/063755A1
Formula (I); Conformationally constrained macrocyclic compounds of formula (I), including substituents E with at least one ester moiety, G and Q, as defined in the description and the claims, and salts thereof, can be metabolized to comp...  
WO/2017/063756A1
Conformationally constrained macrocyclic compounds of formula (I), including substituents E, G, and Q, as defined in the description and the claims, and salts thereof, have the property to modulate the activity of the peptidyl-prolyl cis...  
WO/2017/063757A1
Conformationally constrained macrocyclic compounds of formula (I), including substituents E with at least one ester moiety, G and Q, as defined in the description and the claims, and salts thereof, can be metabolized to compounds that ha...  
WO/2017/066402A1
The present invention provides compounds of Formula (I): wherein all variables are as defined in the specification, and compositions comprising any of such novel compounds. These compounds are APJ agonists which may be used as medicaments.  
WO/2017/066053A1
The present invention relates to therapeutic combinations of anti-bacterial agents linezolid, bedaquiline and pretomanid, and optionally with pyrazinamide, in a short-course oral dosage regimen for the treatment of tuberculosis.  
WO/2017/063754A1
Conformationally constrained macrocyclic compounds of formula (I), including substituents E, G, and Q, as defined in the description and the claims, and salts thereof, have the property to modulate the activity of the peptidyl-prolyl cis...  
WO/2017/029602A3
The present invention relates to novel compounds or pharmaceutically acceptable salts thereof, corresponding pharmaceutical compositions and treatment methods or uses as antibacterials for bacterial infections.  
WO/2017/060406A1
The present invention relates to substituted quinoxaline and pyridopyrazine derivatives of Formula (I) wherein the variables have the meaning defined in the claims. The compounds according to the present invention are useful as pI3Kβ in...  
WO/2017/060322A2
The invention relates to novel conjugates of a binder or a derivative thereof with one or more molecules of an active component, wherein the active component is a CDK9 kinase inhibitor, which is conjugated to the binder via a linker Z as...  
WO/2017/060167A1
The present invention relates to novel modified macrocyclic compounds of general formula (I) as described and defined herein, and methods for their preparation, their use for the treatment and/or prophylaxis of disorders, in particular o...  
WO/2017/062837A1
Topical administration of VEGF inhibitors such as, without limitation, rifamycin compounds are useful for treating skin disorders such as treating and/or reducing scars such as hypertrophic scars, and useful for treating acne and underly...  
WO/2017/056115A1
The present invention provides novel N-aryl containing fused heterocyclic compounds as anticancer agents, especially as estrogen receptor (ER) antagonists/ degraders and process for their preparation.  
WO/2017/055196A1
The present invention relates to novel macrocyclic sulfondiimine compounds of general formula (I) as described and defined herein, and methods for their preparation, their use for the treatment and/or prophylaxis of disorders, in particu...  
WO/2017/055305A1
A series of substituted pyrazolo[1,5-a]pyrimidine and pyrazolo[1,5-a][1,3,5]- triazine derivatives of formula (I), as defined herein, being selective inhibitors of phosphatidylinositol-4-kinase ΙΙΙβ (ΡI4ΚΙΙΙβ) activity, are ben...  
WO/2017/025419A3
The invention relates to novel compounds of formula (I), wherein R1, R2, R3, A1, X and n are defined as cited in the description, to the use thereof as acaricides and/or insecticides for controlling animal pests, and to methods and inter...  
WO/2017/024229A8
A process for the stereoselective synthesis of chiral 3-heterocyclyl-1,2-dihydroxy cyclohexanes is disclosed. The process involves reacting a tricyclic nitrogenous heterocycle with an allyl carbonate in the presence of a chiral palladium...  
WO/2017/049383A1
The present disclosure relates to novel macrocyclic compounds and libraries thereof containing heteroaryl moieties that are useful as research tools for drug discovery efforts. The present disclosure also relates to methods of preparing ...  
WO/2017/051303A1
The present invention is directed to compounds, tautomers and pharmaceutically acceptable salts of the compounds which are disclosed, wherein the compounds have the structure of Formula (I), wherein the variables R1, R2, R3, R4 and X are...  
WO/2017/049711A1
Disclosed are a quinoline derivative, and a pharmaceutical composition, a preparation method and a use thereof. The quinoline derivative of the present invention has a c-Met inhibitory activity and can be used for the treatment, relievin...  
WO/2017/053537A1
Provided herein are methods for treating, preventing, or ameliorating one or more symptoms of a condition, disorder, or disease mediated by a lipid kinase or a protein kinase with benzimidazoles, for example, of Formula I or II, and phar...  
WO/2017/047602A1
Provided is a compound presenting high efficacy in diseases caused by Trichophyton by having excellent antifungal activity against Trichophyton, which is a major causative organism of superficial mycoses. A biaryl derivative represented ...  
WO/2017/046605A1
This invention relates to antibacterial and anti-mycobacterial drug compounds of formula (I). It also relates to pharmaceutical formulations of antibacterial drug compounds of formula (I). It also relates to uses of the derivatives in tr...  
WO/2017/046131A1
Disclosed are processes for preparing solvate forms of Dolutegravir sodium.  
WO/2017/046117A1
Compounds of formula (I) (I) and pharmaceutically acceptable salts thereof, wherein R1, R2 and R3 are as defined in the specification, are useful in treating conditions or disorders prevented by or ameliorated by positive allosteric modu...  
WO/2017/045063A1
The present invention relates to cyclic amino acid molecules, in particular 1,3,4-oxadiazole containing macrocyclic peptides, and a process to produce the same. The process involves the macrocyclization of amino acids or linear peptides....  
WO/2017/046606A1
This invention relates to antibacterial and antimycobacterial drug compounds of formula (I). It also relates to pharmaceutical formulations of antibacterial drug compounds of formula (I). It also relates to uses of the derivatives in tre...  
WO/2017/042182A1
Described herein are tricyclic compounds with phosphoinositide-3 kinase (PI3K) modulation activity or function having the Formula I structure: or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substi...  
WO/2016/131098A8
The present invention provides for certain sulfonyl ureas and related compounds which have advantageous properties and show useful activity in the inhibition of activation of the NLRP3 inflammasome. Such compounds are useful in the treat...  
WO/2017/044720A1
The present invention provides compounds, compositions thereof, and methods of using the same.  
WO/2017/044569A1
A genus of arylsulfonamide derivatives of heterocyclic constrained tricyclic compounds is disclosed. The compounds are of the following genus: The compounds induce FOXO1 transcription factor translocation to the nucleus by modulating PP2...  
WO/2017/038909A1
The present invention provides a heterocyclic compound a TLR7 and/or TLR9 and/or TLR-7/8/9 and/or TLR-7/8 and/or TLR-7/9 inhibitory action, which is useful as an agent for the prophylaxis or treatment of autoimmune diseases and/or inflam...  
WO/2017/040877A1
The invention provides heterobicyclic pyrimidinone compounds, compositions containing such compounds, medical kits, and methods for using such compounds and compositions to treat medical disorders, e.g., Gaucher disease, Parkinson's dise...  
WO/2017/037670A1
Disclosed are amino triazole compounds substituted with a piperidinyl ring that is itself substituted with a heterocyclic ring. These compounds are inhibitors of acidic mammalian chitinase and chitotriosidase. Also disclosed are methods ...  
WO/2017/040341A1
In various embodiments novel rapamycin analogs are provides that show improved mTORC1 specificity.  
WO/2017/034420A1
Pharmaceutical compositions comprising 3-aminoisoxazolopyridine compounds of the Formula I having IDO1 and/or TDO inhibitory activity are described, where W is CR1, N or N-oxide; X is CR2, N or N-oxide; Y is CR3, N or N-oxide; Z is CR4, ...  
WO/2017/029602A2
The present invention relates to novel compounds or pharmaceutically acceptable salts thereof, corresponding pharmaceutical compositions and treatment methods or uses as antibacterials for bacterial infections.  
WO/2017/026538A1
The present invention relates to a method of industrially advantageous production of a pyrazine compound. The present invention is a method of producing compound (b) by subjecting compound (a) to an intramolecular ring closing reaction u...  
WO/2017/027249A1
Methods of sedating a patient undergoing critical care treatment using intravenous gaboxadol or a pharmaceutically acceptable salt thereof are provided. Parenteral formulations for critical care sedation using intravenous gaboxadol or a ...  
WO/2017/025031A1
Disclosed is a diazaoxa heterocyclic spiro-dione piperazine alkaloid derivative having an antiviral activity and a preparation method thereof. The compound is a compound of formula (I), has anti-RSV, HSV-1 and EV71 activities and has the...  

Matches 701 - 750 out of 14,479